Progyny, Inc. Announces Third Quarter 2020 Results
Progyny, a leader in fertility benefits management, reported third quarter 2020 revenue of $98.9 million, up 62% from prior year. Net income hit $5.4 million, reversing an $8.2 million loss year-over-year. The company anticipates 2020 revenue guidance of $340-$345 million, targeting a growth of 48%-50%. For 2021, Progyny projects a minimum of $525 million in revenue with 180 clients covering 2.7 million lives. Adjusted EBITDA nearly doubled to $10.6 million, demonstrating strong operational leverage despite COVID-19.
- Third quarter revenue reached $98.9 million, a 62% increase from $61.2 million in Q3 2019.
- Net income improved to $5.4 million from an $8.2 million loss year-over-year.
- 2020 revenue guidance raised to $340-$345 million, representing a growth of 48%-50%.
- Adjusted EBITDA increased to $10.6 million, nearly doubling from the prior year.
- Projected 2021 revenue of at least $525 million, reflecting 53% growth from 2020 guidance.
- None.
Reports Record Third Quarter Revenue of
Raises Revenue Guidance to
Affirms Preliminary View of a Minimum of
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced its financial results for the three-month period ended September 30, 2020 (“the third quarter of 2020”) as compared to the three-month period ended September 30, 2019 (“the prior year period”).
“Progyny had a very strong third quarter, reflecting record quarterly revenues and profitability,” said David Schlanger, Chief Executive Officer of Progyny. “Our 2020 selling season is now largely complete, and the results were consistent with our expectations, both in terms of new sales and new covered lives. We have received commitments to date from 45 new clients for 2021, representing approximately 400,000 new covered lives, while also building a very robust pipeline of opportunities to pursue in next year’s selling season.”
“Our results this quarter demonstrate the growing demand for our benefit as well as our operating leverage as the business grows. Revenue grew
Third Quarter 2020 Highlights:
| (unaudited; in thousands, except per share amounts) | 3Q 2020 | 3Q 2019 | ||||
| Revenue | ||||||
| Gross Profit | ||||||
| Gross Margin | 21.1 | % | 20.1 | % | ||
| Net Income (Loss) | ) | |||||
| Net Income (Loss) per Share Attributable to Common Stockholders1 | ) | |||||
| Adjusted EBITDA2 | ||||||
| Adjusted EBITDA Margin2 | 10.7 | % | 9.0 | % | ||
- Net income (loss) per share attributable to common stockholders reflects weighted-average shares outstanding as adjusted for potential dilutive securities, including options to purchase common stock and warrants to purchase common stock. Note the company effected a 1-for-4.5454 reverse stock split of its common stock and convertible preferred stock on October 14, 2019. For ease of comparability, all periods presented in this release retroactively give effect to the reverse stock split as if it occurred at the beginning of the periods presented.
- Adjusted EBITDA and Adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, U.S. GAAP. Please see Annex A of this release for a reconciliation of Adjusted EBITDA to Net income (loss), the most directly comparable financial measure stated in accordance with GAAP for each of the periods presented.
Financial Highlights
Revenue was
- Fertility benefit services revenue was
$73.1 million , a46% increase from the$50.0 million reported in the prior year period, primarily as a result of the increase in our number of clients and covered lives. - Pharmacy benefit services revenue was
$25.8 million , a131% increase as compared to the$11.2 million reported in the prior year period. The growth in pharmacy benefit services revenue was primarily driven by an increase in the number of clients that are providing the pharmacy benefit as compared to the prior year period.
Gross profit was
Net income was
Adjusted EBITDA was
Readers are encouraged to review Annex A for a reconciliation of Adjusted EBITDA to net income.
Cash Flow
Net cash provided by operating activities for the third quarter of 2020 was
Balance Sheet and Financial Position
As of September 30, 2020, the company had total working capital of approximately
Key Metrics
The company had 135 clients as of September 30, 2020, which compared to 84 clients in the prior year period.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
| 2020 | 2019 | 2020 | 2019 | |||||
| ART Cycles* | 5,407 | 3,763 | 13,284 | 9,768 | ||||
| Utilization – All Members** | 0.51 | % | 0.52 | % | 0.92 | % | 1.08 | % |
| Utilization – Female Only** | 0.44 | % | 0.47 | % | 0.78 | % | 0.94 | % |
| Average Members | 2,221,000 | 1,356,000 | 2,156,000 | 1,240,000 | ||||
* Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers, and egg freezing.
** Represents the member utilization rate for all services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period, while the utilization rate for female only includes only unique females who utilize the benefit during that period. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods.
Financial Outlook
The company is providing the following financial guidance for the full year and three-month period ending December 31, 2020:
- Full Year 2020 Outlook:
- Revenue is projected to be
$340.0 million to$345.0 million , reflecting growth of48% to50% - Net income is projected to be
$12.7 million to$14.2 million , or$0.13 t o$0.14 per share, on the basis of approximately 100 million assumed weighted-average fully diluted-shares outstanding - Adjusted EBITDA1 is projected to be
$29.7 million to$31.0 million
- Revenue is projected to be
- Fourth Quarter of 2020 Outlook:
- Revenue is projected to be
$95.4 million to$100.4 million , reflecting growth of47% to54% - Net income is projected to be
$5.1 million to$6.6 million , or$0.05 t o$0.07 per share, on the basis of approximately 100 million assumed weighted-average fully diluted-shares outstanding - Adjusted EBITDA1 is projected to be
$9.0 million to$10.3 million
- Revenue is projected to be
“Our newest clients from the 2020 selling season represent a broad cross-section of over 20 industries – including financial services, pharmaceuticals, business services, consumer products, technology, and transportation – which will further enhance the strength and diversity within our existing client base,” said Pete Anevski, Progyny’s President and Chief Operating Officer. “By providing a comprehensive fertility benefit through Progyny, these companies are demonstrating their commitment to their employees’ health, driven by our industry leading outcomes, while also showing their leadership by supporting diversity, equality and inclusion across their workforce.
“Looking ahead, we expect to enter 2021 with 180 total clients, representing 2.7 million covered lives, and as such, we are affirming our preliminary expectations for a minimum of
1. Adjusted EBITDA is a financial measure that is not required by, or presented in accordance with, U.S. GAAP. Please see Annex A of this release for a reconciliation of forward-looking Adjusted EBITDA to forward-looking net loss, the most directly comparable financial measure stated in accordance with GAAP for the period presented.
Conference Call Information
Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) today to discuss its financial results. Interested participants from the United States may join by calling 1.866.825.7331 and using conference ID 265484. Participants from international locations may join by calling 1.973.413.6106 and using the same conference ID. A replay of the call will be available until November 12, 2020 at 11:59 P.M. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484. A live audio webcast of the call and subsequent replay will also be available through the Events & Presentations section of the Company’s Investor Relations website at investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a leading fertility benefits management company in the US. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive fertility solution can simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation’s leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.
Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, statements regarding our positioning to successfully manage the impact of COVID-19 and the associated economic uncertainty on our business, our financial outlook for the fourth quarter and full year 2020 and full year 2021, our client and member outlook for 2021, our ability to retain existing clients and acquire new clients, and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future,” “project,” and the negative of these or similar terms and phrases are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of fertility procedures and other impacts to the business; failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability in the future; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenues; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; unfavorable conditions in our industry or the United States economy, such as conditions resulting from outbreaks of contagious diseases including COVID-19; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the medical landscape, regulations, client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; our ability to maintain our company culture; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain or any disruption of our pharmacy distribution network; our relationship with key pharmaceutical manufacturers or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to potential sales to government entities; our ability to protect our intellectual property rights; risks related to any litigation against us; risks related to acquisitions, strategic investments, partnerships, or alliances; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a significant portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting and the increased costs of operating as a public company. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020, and subsequent reports that we file with the SEC which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons. Actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying tables include a non-GAAP financial measure, Adjusted EBITDA.
Adjusted EBITDA is a supplemental financial measure that is not required by, or presented in accordance with, GAAP. We believe that Adjusted EBITDA, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is a measure used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.
Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating expenses, including interest expense, net; (5) it does not consider the impact of any stock warrant valuation adjustment; (6) it does not reflect tax payments that may represent a reduction in cash available to us; (7) it does not include legal fees that may be payable in connection with a vendor arbitration; and (8) it does not include non-deferred costs associated with the IPO. In addition, our Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net income from continuing operations and other GAAP results.
We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; other income; interest (income) expense, net; convertible preferred stock warrant valuation adjustment; provision for income taxes and legal fees associated with a vendor arbitration. Please see Annex A: “Reconciliation of GAAP to Non-GAAP Financial Measures” elsewhere in this press release.
For Further Information, Please Contact:
Investors:
James Hart
investors@progyny.com
Media:
Selena Yang
media@progyny.com
PROGYNY, INC.
Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
| September 30, | December 31, | |||||||
| 2020 | 2019 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 53,965 | $ | 80,382 | ||||
| Marketable securities | 50,995 | — | ||||||
| Accounts receivable, net of | 78,302 | 47,059 | ||||||
| Prepaid expenses and other current assets | 1,328 | 5,003 | ||||||
| Total current assets | 184,590 | 132,444 | ||||||
| Property and equipment, net | 3,506 | 3,083 | ||||||
| Goodwill | 11,880 | 11,880 | ||||||
| Intangible assets, net | 1,483 | 2,375 | ||||||
| Other noncurrent assets | 592 | 652 | ||||||
| Total assets | $ | 202,051 | $ | 150,434 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 42,210 | $ | 19,388 | ||||
| Accrued expenses and other current liabilities | 31,956 | 16,775 | ||||||
| Total current liabilities | 74,166 | 36,163 | ||||||
| Other noncurrent liabilities | 617 | — | ||||||
| Total liabilities | 74,783 | 36,163 | ||||||
| Commitments and Contingencies (Note 7) | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Common stock, | 9 | 8 | ||||||
| Additional paid-in capital | 234,134 | 228,755 | ||||||
| Treasury stock, at cost, | (1,009 | ) | (1,009 | ) | ||||
| Accumulated deficit | (105,883 | ) | (113,483 | ) | ||||
| Accumulated other comprehensive income | 17 | — | ||||||
| Total stockholders’ equity | 127,268 | 114,271 | ||||||
| Total liabilities and stockholders’ equity | $ | 202,051 | $ | 150,434 | ||||
PROGYNY, INC.
Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Revenue | $ | 98,928 | $ | 61,196 | $ | 244,557 | $ | 164,561 | |||||||
| Cost of services | 78,092 | 48,876 | 195,164 | 130,825 | |||||||||||
| Gross profit | 20,836 | 12,320 | 49,393 | 33,736 | |||||||||||
| Operating expenses: | |||||||||||||||
| Sales and marketing | 3,355 | 3,183 | 10,230 | 8,646 | |||||||||||
| General and administrative | 12,120 | 6,068 | 31,763 | 16,557 | |||||||||||
| Total operating expenses | 15,475 | 9,251 | 41,993 | 25,203 | |||||||||||
| Income from operations | 5,361 | 3,069 | 7,400 | 8,533 | |||||||||||
| Other income (expense): | |||||||||||||||
| Other income | 11 | — | 178 | — | |||||||||||
| Interest income (expense), net | (17 | ) | (28 | ) | 138 | (194 | ) | ||||||||
| Convertible preferred stock warrant valuation adjustment | — | (11,226 | ) | — | (12,419 | ) | |||||||||
| Total other income (expense), net | (6 | ) | (11,254 | ) | 316 | (12,613 | ) | ||||||||
| Income (loss) before income taxes | 5,355 | (8,185 | ) | 7,716 | (4,080 | ) | |||||||||
| Provision for income taxes | — | 25 | 116 | 89 | |||||||||||
| Net income (loss) | $ | 5,355 | $ | (8,210 | ) | $ | 7,600 | $ | (4,169 | ) | |||||
| Net income (loss) per share attributable to common stockholders: | |||||||||||||||
| Basic | $ | 0.06 | $ | (1.10 | ) | $ | 0.09 | $ | (0.70 | ) | |||||
| Diluted | $ | 0.05 | $ | (1.10 | ) | $ | 0.08 | $ | (0.70 | ) | |||||
| Weighted-average shares used in computing net earnings (loss) per share: | |||||||||||||||
| Basic | 86,265,297 | 7,472,469 | 85,364,608 | 5,947,821 | |||||||||||
| Diluted | 98,969,588 | 7,472,469 | 98,936,489 | 5,947,821 | |||||||||||
PROGYNY, INC.
Statements of Cash Flows
(Unaudited)
(in thousands)
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2020 | 2019 | |||||||
| OPERATING ACTIVITIES | ||||||||
| Net income | $ | 7,600 | $ | (4,169 | ) | |||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Deferred tax expense | 116 | 89 | ||||||
| Non-cash interest expense | 56 | — | ||||||
| Depreciation and amortization | 1,442 | 1,594 | ||||||
| Stock-based compensation expense | 8,661 | 3,209 | ||||||
| Bad debt expense | 3,709 | 1,332 | ||||||
| Loss on disposal of property and equipment | — | 1 | ||||||
| Change in fair value of warrant liabilities | — | 12,419 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (34,952 | ) | (22,344 | ) | ||||
| Prepaid expenses and current other assets | 3,619 | (452 | ) | |||||
| Accounts payable | 23,719 | 6,824 | ||||||
| Accrued expenses and other current liabilities | 15,019 | 6,119 | ||||||
| Other noncurrent assets and liabilities | 677 | (667 | ) | |||||
| Net cash provided by operating activities | 29,666 | 3,955 | ||||||
| INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment, net | (940 | ) | (678 | ) | ||||
| Purchases of marketable securities | (64,978 | ) | — | |||||
| Sales of marketable securities | 14,000 | — | ||||||
| Net cash (used in) continuing operations | (51,918 | ) | (678 | ) | ||||
| Net cash provided by discontinued operations | — | 200 | ||||||
| Net cash (used in) provided by investing activities | (51,918 | ) | (478 | ) | ||||
| FINANCING ACTIVITIES | ||||||||
| Payment of initial public offering costs | (892 | ) | (512 | ) | ||||
| Proceeds from revolving line of credit | — | 157,850 | ||||||
| Repayments made against revolving line of credit | — | (158,103 | ) | |||||
| Repurchase of common stock | — | (182 | ) | |||||
| Proceeds from exercise of stock options | 2,078 | 5,007 | ||||||
| Payment of employee taxes related to equity awards | (6,419 | ) | — | |||||
| Proceeds from contributions to employee stock purchase plan | 1,068 | — | ||||||
| Net cash (used in) provided by financing activities | (4,165 | ) | 4,060 | |||||
| Net increase (decrease) in cash and cash equivalents | (26,417 | ) | 7,537 | |||||
| Cash and cash equivalents, beginning of period | 80,382 | 127 | ||||||
| Cash and cash equivalents, end of period | $ | 53,965 | $ | 7,664 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||
| Cash paid for interest | $ | — | $ | 176 | ||||
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Additions of property and equipment, net included in accounts payable and accrued expenses | $ | 33 | $ | — | ||||
| Deferred initial public offering costs in accounts payable and accrued expenses | $ | — | $ | 2,308 | ||||
ANNEX A
PROGYNY, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(unaudited)
(in thousands)
Adjusted EBITDA and Adjusted EBITDA Margin on Incremental Revenue Calculation
The following table provides a reconciliation of Net income (loss) to Adjusted EBITDA for each of the periods presented:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net income (loss) | $ | 5,355 | $ | (8,210 | ) | $ | 7,600 | $ | (4,169 | ) | ||||||
| Add: | ||||||||||||||||
| Depreciation and amortization | 462 | 535 | 1,442 | 1,595 | ||||||||||||
| Stock‑based compensation | 3,071 | 1,680 | 8,661 | 3,209 | ||||||||||||
| Other income | (11 | ) | - | (178 | ) | - | ||||||||||
| Interest (income) expense, net | 17 | 28 | (138 | ) | 194 | |||||||||||
| Convertible preferred stock warrant valuation adjustment | - | 11,226 | - | 12,419 | ||||||||||||
| Provision for income taxes | - | 25 | 116 | 89 | ||||||||||||
| Legal fees associated with a vendor arbitration(a) | 1,688 | 247 | 3,232 | 973 | ||||||||||||
| Non-deferred IPO costs | - | - | - | 150 | ||||||||||||
| Adjusted EBITDA | $ | 10,582 | $ | 5,531 | $ | 20,735 | $ | 14,460 | ||||||||
| Revenue | $ | 98,928 | $ | 61,196 | ||||||||||||
| Incremental revenue vs. 2019 | $ | 37,732 | ||||||||||||||
| Incremental Adjusted EBITDA vs. 2019 | $ | 5,051 | ||||||||||||||
| Add: | ||||||||||||||||
| One time step-up in incremental public company expenses | 1,944 | |||||||||||||||
| Incremental Adj EBITDA excluding one-time step-up in incremental public company expenses | $ | 6,995 | ||||||||||||||
| Incremental Adj EBITDA margin on incremental revenue excluding one-time step-up in incremental public company expenses | 18.5 | % | ||||||||||||||
(a) We engaged in other activities and transactions that can impact our net income. In recent periods, these other items included, but were not limited to, legal fees related to an arbitration resulting from our termination of an agreement with a specialty pharmacy vendor.
Reconciliation of Non-GAAP Financial Guidance for the Three Months and Year Ending December 31, 2020
| Three Months Ending December 31, 2020 | Year Ending December 31, 2020 | |||||||||||||||
| (in thousands) | Low | High | Low | High | ||||||||||||
| Revenue | $ | 95,443 | $ | 100,443 | $ | 340,000 | $ | 345,000 | ||||||||
| Net Income | $ | 5,068 | $ | 6,568 | $ | 12,668 | $ | 14,168 | ||||||||
| Add: | ||||||||||||||||
| Depreciation and amortization | 458 | 458 | 1,900 | 1,900 | ||||||||||||
| Stock-based compensation | 3,539 | 3,239 | 12,200 | 11,900 | ||||||||||||
| Other income | (22 | ) | (22 | ) | (200 | ) | (200 | ) | ||||||||
| Interest expense (income), net | (62 | ) | (62 | ) | (200 | ) | (200 | ) | ||||||||
| Provision (benefit) for income taxes | (16 | ) | 84 | 100 | 200 | |||||||||||
| Legal fees associated with a vendor arbitration | - | - | 3,232 | 3,232 | ||||||||||||
| Adjusted EBITDA* | $ | 8,965 | $ | 10,265 | $ | 29,700 | $ | 31,000 | ||||||||
* All of the numbers in the table above reflect our future outlook as of the date hereof. Net income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, such as legal fees associated with a vendor arbitration, nor do they contemplate any adjustment of the valuation allowance related to the deferred tax assets.
FAQ
What were Progyny's third quarter 2020 financial results?
What is Progyny's revenue guidance for 2020?
What is Progyny's projected revenue for 2021?
How did Progyny's adjusted EBITDA perform in Q3 2020?
How many clients did Progyny gain for 2021?
